 |
1 Disease |  |
5 Trials |
|
5 Trials |  |
395 News |  |
| «123456 |
- | Zynteglo (betibeglogene autotemcel) / bluebird bio
Gene therapy: NORTHSTAR: A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in ?-Thalassemia Major Participants (clinicaltrials.gov) - May 8, 2015
P1/2, N=18, Recruiting, Sponsor: bluebird bio
N=15 --> 18
- Lyfgenia (lovotibeglogene autotemcel) / bluebird bio
Enrollment open, Gene therapy, Viral vector: HGB-206: A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease (clinicaltrials.gov) - Aug 27, 2014
P1, N=8, Recruiting, Sponsor: bluebird bio
N=15 --> 18 Not yet recruiting --> Recruiting
- Zynteglo (betibeglogene autotemcel) / bluebird bio
New P1/2 trial, Gene therapy: HGB-205: A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in ?-Thalassemia Major (Also Referred to as Transfusion-dependent ?-Thalassemia [TDT]) and Sickle Cell Disease (clinicaltrials.gov) - May 28, 2014
P1/2, N=7, Recruiting, Sponsor: bluebird bio
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Lyfgenia (lovotibeglogene autotemcel) / bluebird bio
New P1 trial, Gene therapy, Viral vector: HGB-206: A Study Evaluating the Safety and Efficacy of Lovo-cel in Severe Sickle Cell Disease (clinicaltrials.gov) - May 14, 2014
P1, N=8, Not yet recruiting, Sponsor: bluebird bio
- Zynteglo (betibeglogene autotemcel) / bluebird bio
Gene therapy: HGB-205: A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in ?-Thalassemia Major (Also Referred to as Transfusion-dependent ?-Thalassemia [TDT]) and Sickle Cell Disease (clinicaltrials.gov) - May 13, 2014
P1/2, N=7, Recruiting, Sponsor: bluebird bio
- | Zynteglo (betibeglogene autotemcel) / bluebird bio
Gene therapy: NORTHSTAR: A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in ?-Thalassemia Major Participants (clinicaltrials.gov) - Aug 27, 2013
P1/2, N=15, Recruiting, Sponsor: bluebird bio
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Zynteglo (betibeglogene autotemcel) / bluebird bio
New P1/2 trial, Gene therapy: NORTHSTAR: A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in ?-Thalassemia Major Participants (clinicaltrials.gov) - Dec 5, 2012
P1/2, N=15, Recruiting, Sponsor: bluebird bio